Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Cingulate Inc. - Warrants
No Price
15.04.2026 19:28
Current Prices from Cingulate Inc. - Warrants
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ
CINGW
USD
15.04.2026 19:28
0,02 USD
-
Share Float & Liquidity
Free Float97,82 %
Shares Float6,61 M
Shares Outstanding6,75 M
Company Profile for Cingulate Inc. - Warrants Share
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
